论文部分内容阅读
[目的]探讨雌激素受体(ER)和HER-2在新辅助化疗乳腺癌组织的表达及临床意义。[方法]采用免疫组织化学方法检测100例乳腺癌患者新辅助化疗前后肿瘤组织中ER及HER-2的表达,并与疗效作相关性分析。[结果]新辅助化疗总有效率79%,ER阴性表达者化疗有效率明显高于ER阳性者(P<0.05),HER-2表达与疗效无明显关系(P>0.05)。化疗后ER、HER-2的表达未见显著性变化(P>0.05)。[结论]新辅助化疗对ER、HER-2表达状态无显著影响。ER对乳腺癌新辅助化疗疗效有一定预测价值。
[Objective] To investigate the expression and clinical significance of estrogen receptor (ER) and HER-2 in neoadjuvant chemotherapy of breast cancer. [Method] The expression of ER and HER-2 in 100 cases of breast cancer patients before and after neoadjuvant chemotherapy were detected by immunohistochemistry and correlated with the curative effect. [Results] The total effective rate of neoadjuvant chemotherapy was 79%. The effective rate of chemotherapy in ER-negative patients was significantly higher than that in ER-positive patients (P <0.05). There was no significant correlation between HER-2 expression and therapeutic effect (P> 0.05). The expression of ER and HER-2 did not change significantly after chemotherapy (P> 0.05). [Conclusion] Neoadjuvant chemotherapy has no significant effect on the expression of ER and HER-2. ER on the efficacy of neoadjuvant chemotherapy for breast cancer has a certain predictive value.